HeartBeam (NASDAQ:BEAT) Issues Quarterly Earnings Results

HeartBeam (NASDAQ:BEAT) issued its quarterly earnings results on Wednesday. The medical research company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.02, FiscalAI reports.

Here are the key takeaways from HeartBeam’s conference call:

• HeartBeam said it has now established flagship commercial accounts in all four target geographies — New York City, Dallas, South Florida and Southern California — through partnerships with ClearCardio and Atelier Health, giving the company an initial foothold in its direct-pay market.
• Management said the limited commercial launch is getting strong early physician reception, with clinicians viewing the product as a differentiated, medical-grade 12-lead ECG that can be used anytime, anywhere, rather than relying on traditional in-office or emergency department testing.
• The ALIGN-ACS pilot study for heart-attack detection is enrolling ahead of schedule, and the company expects to complete enrollment by the end of Q3 2026, using the data to inform a future FDA pivotal study and potential indication expansion.
• HeartBeam completed its first working prototype of the on-demand 12-lead patch and has begun a pilot ischemia study in Europe, while continuing partnership discussions for a $2 billion ambulatory monitoring market opportunity.
• The company strengthened its balance sheet with an $11.5 million financing and ended the quarter with just over $2 million in cash; management said pro forma cash would be about $12.4 million and now expects full-year 2026 cash outflow below $16 million, better than prior guidance.

HeartBeam Stock Performance

Shares of BEAT stock traded up $0.10 during trading hours on Wednesday, hitting $1.01. 1,578,367 shares of the company were exchanged, compared to its average volume of 1,331,990. The company has a 50 day simple moving average of $1.13 and a two-hundred day simple moving average of $1.52. The firm has a market cap of $41.50 million, a P/E ratio of -1.63 and a beta of -0.86. HeartBeam has a fifty-two week low of $0.54 and a fifty-two week high of $4.00.

Insider Buying and Selling

In related news, Director Mark E. Strome bought 750,000 shares of the business’s stock in a transaction that occurred on Thursday, April 16th. The shares were acquired at an average cost of $0.80 per share, with a total value of $600,000.00. Following the completion of the purchase, the director directly owned 3,650,000 shares in the company, valued at $2,920,000. The trade was a 25.86% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Richard Ferrari purchased 62,500 shares of HeartBeam stock in a transaction on Thursday, April 16th. The stock was bought at an average price of $0.80 per share, with a total value of $50,000.00. Following the completion of the acquisition, the director directly owned 291,636 shares of the company’s stock, valued at approximately $233,308.80. This trade represents a 27.28% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 1,118,750 shares of company stock valued at $895,000 over the last ninety days. 18.04% of the stock is owned by corporate insiders.

Institutional Trading of HeartBeam

Several large investors have recently made changes to their positions in BEAT. Virtu Financial LLC acquired a new position in HeartBeam during the 4th quarter worth approximately $70,000. State Street Corp increased its holdings in shares of HeartBeam by 60.1% during the fourth quarter. State Street Corp now owns 125,473 shares of the medical research company’s stock valued at $301,000 after acquiring an additional 47,100 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of HeartBeam during the fourth quarter worth approximately $55,000. Insigneo Advisory Services LLC bought a new position in shares of HeartBeam in the 4th quarter worth $74,000. Finally, CIBC Private Wealth Group LLC acquired a new stake in HeartBeam in the 4th quarter valued at $26,000. 7.77% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

BEAT has been the subject of a number of analyst reports. B. Riley Financial began coverage on shares of HeartBeam in a research note on Tuesday, March 31st. They set a “buy” rating and a $4.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and set a $5.50 price target on shares of HeartBeam in a research report on Monday, March 16th. Finally, D. Boral Capital lowered HeartBeam from a “buy” rating to a “hold” rating in a research report on Monday, April 20th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $4.80.

HeartBeam Company Profile

BioTelemetry, Inc, a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core laboratory services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in two segments, Healthcare and Research. The Healthcare segment focuses on the remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which enable physicians to prescribe wireless event, digital loop event, memory loop event, memory loop event, and non-loop event monitors.